＜5616＞ Rain Wind Sun 1099 -112

A sharp decline. The Tokyo Stock Exchange announced from the 6th that the contract deposit rate relating to new sales and purchases through margin trading of the company's shares will be 50% or more (of which 20% or more in cash), and sales that are disgusted with this have become dominant. Furthermore, Japan Securities Finance also implemented additional security deposit collection measures, and after the same day, it was decided that the loan guarantee ratio for loan transaction self transactions and liquidation intermediary loan transaction self transactions for each non-liquidation participant will be 50% (of which 20% is cash collateral).

＜6550＞ Unipos 178 +50

Stop height. It was announced that they have begun providing a culture change service “Culture Transformation for Succession,” which specializes in organizations before and after business succession, and purchases that were well received are ahead. Based on know-how cultivated through organization building support for over 370 companies, it is a service that responds to concerns and needs unique to business succession, and provides a set of places, know-how, systems, and contents in order to concretely promote cultural change before and after business succession.

＜4014＞ Body Note 730 +97

Temporary stop high, year-to-date high price update. Today, it was announced that collaboration has begun with Medley, which provides Japan's largest medical and nursing care recruitment site “Job Medley,” to promote the activities of potential nurses and caregivers, and it is viewed as good news. The company's life event data and matching know-how is thought to contribute to promoting the activities of potential human resources in the medical healthcare field, and it is said that collaboration with Medley, which now provides 0.45 million or more job information (as of 24/9) in the medical healthcare field, has been reached.

＜4890＞ Tsubota Lab 502 +80

The stop is high. China's leading ophthalmic drug manufacturer “Shenyang Xingqi Pharmaceutical Co. It was announced that a patent license agreement was signed with “, Ltd.” granting exclusive license rights for specific patents in specific regions. “Xingqi” is a major pharmaceutical manufacturer specializing in research and development, manufacture, and sales of ophthalmic pharmaceuticals in China, and the total contract fee is 18 million US dollars (approximate amount of 2.68 billion yen in Japanese yen). Under the same agreement, treatments based on patents held by the company are offered in China

The purpose is to make it widely available.

＜4586＞ Medlec 97-4

Continued decline. It has been announced that a patent assessment has been notified by the Patent Office for the “laminated adhesive” that is pending after the transaction ended on the 5th. The patent relates to the structure of a patch agent, and it is a technology that realizes functional improvements such as improving adhesiveness by intentionally installing a fixed space, and is used in the spastic paralysis treatment drug MRX-4TZT (tizanidine tape agent). The patent is valid until 2040, and they are also aiming to obtain rights in the United States, Europe, and China.

＜4592＞ Sun Bio 938 -33

Continued decline. After the transaction ended on the 5th, it was announced that the analysis results of the phase 2 stemtra test of the main development product SB623 were published in Neurology. It is said that analysis results evaluating the efficacy and safety up to 48 weeks (final) of the Phase 2 multi-center joint pseudosurgery control randomized double blind comparison test (STEMTRA test) aimed at examining the efficacy and safety of the main development product SB623 were published for patients with chronic motor dysfunction due to traumatic brain injury performed from 2016 to 2019.